Instituto Universitario de Tecnologías Biomédicas
Instituto de investigación
Instituto de Biomedicina de Sevilla
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Biomedicina de Sevilla (11)
2024
-
Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice
Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 12, pp. 1604-1615
-
Predictive factors for decompensating events in patients with cirrhosis with primary biliary cholangitis under different lines of therapy
Hepatology (Baltimore, Md.), Vol. 80, Núm. 4, pp. 791-806
-
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis
Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597
2022
-
Novel genes and sex differences in COVID-19 severity
Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806
-
Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes
Gut, Vol. 71, Núm. 10, pp. 2138-2140
2021
-
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects
Liver International, Vol. 41, Núm. 9, pp. 2076-2086
2020
2019
-
Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH
Gastroenterologia y Hepatologia, Vol. 42, Núm. 10, pp. 657-676
2018
-
Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline
Gastroenterologia y Hepatologia, Vol. 41, Núm. 5, pp. 328-349
-
Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349] (S0210570518300037) (10.1016/j.gastrohep.2017.12.003))
Gastroenterologia y Hepatologia